ABEO News & Events

Reports Q1 revenue $8.72M, consensus $4.94M. "We are excited that an increasing number of patients at our QTCs are getting scheduled for ZEVASKYN slots this quarter," said Vish Seshadri, president and CEO of Abeona Therapeutics. "We're encouraged by the recent acceleration of onboarding efforts of QTCs to activate, so they can begin to treat patients with ZEVASKYN."

Reports 2025 revenue $5.8M, consensus $4.82M. "2026 is about building a steady cadence of biopsies and treatments," said CEO Vish Seshadri. "We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us to scale-up ZEVASKYN in 2026 and beyond."

Abeona Therapeutics announced an update on the building momentum in the Company's launch of FDA-approved Zevaskyn, a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, RDEB. Following the optimization of a release assay in 2025, Zevaskyn commercial launch activities commenced in the fourth quarter, with the first patient treatment completed in December prior to a mandatory scheduled facility shutdown. Since resuming manufacturing in late January 2026, multiple biopsies have been collected, a patient has completed treatment with Zevaskyn, and there are ongoing manufacturing runs. Additional biopsies are scheduled for the remainder of this quarter.